Literature DB >> 22824819

Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema.

Elsa Solà1, Hugh Watson, Isabel Graupera, Fanny Turón, Rogelio Barreto, Ezequiel Rodríguez, Marco Pavesi, Vicente Arroyo, Mónica Guevara, Pere Ginès.   

Abstract

BACKGROUND & AIMS: Hyponatremia is common in patients with cirrhosis and ascites and is associated with significant neurological disturbances. However, its potential effect on health-related quality of life (HRQL) in cirrhosis has not been investigated. We aimed at assessing the relationship between serum sodium concentration and other clinical and analytical parameters on HRQL in cirrhosis with ascites.
METHODS: A total of 523 patients with cirrhosis and ascites were prospectively investigated. Assessment of HRQL was done with the Medical Outcomes Study Short-Form 36 (SF-36) questionnaire, which is divided into 8 domains, summarized in two components: physical component score (PCS) and mental component score (MCS). Demographic, clinical, and analytical data at baseline were analyzed for their relationship with HRQL.
RESULTS: In multivariate analysis, independent predictive factors associated with an impaired PCS were non-alcoholic etiology of cirrhosis, severe ascites, history of previous episodes of hepatic encephalopathy and falls, presence of leg edema, and low serum sodium concentration. With respect to MCS, only two factors were associated with the independent predictive value: low serum sodium concentration and treatment with lactulose or lactitol. In both components, the scores decreased in parallel with the reduction in serum sodium concentration. Variables more commonly associated with the independent predictive value in the individual 8 domains of PCS and MCS were presence of leg edema and serum sodium concentration, 7 and 6 domains, respectively.
CONCLUSIONS: Serum sodium concentration and presence of leg edema are major factors of the impaired HRQL in patients with cirrhosis and ascites.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824819     DOI: 10.1016/j.jhep.2012.07.020

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  38 in total

1.  Factors contributing to the development of overt encephalopathy in liver cirrhosis patients.

Authors:  Motoh Iwasa; Ryosuke Sugimoto; Rumi Mifuji-Moroka; Nagisa Hara; Kyoko Yoshikawa; Hideaki Tanaka; Akiko Eguchi; Norihiko Yamamoto; Kazushi Sugimoto; Yoshinao Kobayashi; Hiroshi Hasegawa; Yoshiyuki Takei
Journal:  Metab Brain Dis       Date:  2016-06-29       Impact factor: 3.584

2.  Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.

Authors:  Ai Nakagawa; Masanori Atsukawa; Akihito Tsubota; Chisa Kondo; Tomomi Okubo; Taeang Arai; Norio Itokawa; Yoshiyuki Narahara; Katsuhiko Iwakiri
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 3.  Electrolyte and Acid-Base Disturbances in End-Stage Liver Disease: A Physiopathological Approach.

Authors:  José Víctor Jiménez; Diego Luis Carrillo-Pérez; Rodrigo Rosado-Canto; Ignacio García-Juárez; Aldo Torre; David Kershenobich; Eduardo Carrillo-Maravilla
Journal:  Dig Dis Sci       Date:  2017-05-13       Impact factor: 3.199

Review 4.  Multidisciplinary management of patients with cirrhosis: a need for care coordination.

Authors:  Jessica L Mellinger; Michael L Volk
Journal:  Clin Gastroenterol Hepatol       Date:  2012-11-06       Impact factor: 11.382

5.  Long-term quality of life of liver transplant recipients beyond 60 years of age.

Authors:  G Werkgartner; D Wagner; S Manhal; A Fahrleitner-Pammer; H J Mischinger; M Wagner; R Grgic; R E Roller; D Kniepeiss
Journal:  Age (Dordr)       Date:  2013-03-26

6.  Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis.

Authors:  Tomoharu Yamada; Takamasa Ohki; Yuki Hayata; Yuki Karasawa; Satoshi Kawamura; Daisaku Ito; Kentaro Kojima; Michiharu Seki; Nobuo Toda; Kazumi Tagawa
Journal:  Clin Drug Investig       Date:  2016-10       Impact factor: 2.859

Review 7.  Contemporary Epidemiology of Cirrhosis.

Authors:  Jad A Baki; Elliot B Tapper
Journal:  Curr Treat Options Gastroenterol       Date:  2019-06

8.  Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites.

Authors:  Myrte Neijenhuis; Tom J G Gevers; Thomas D Atwell; Tim J Gunneson; Amanda C Schimek; Wietske Kievit; Joost P H Drenth; Patrick S Kamath
Journal:  Am J Gastroenterol       Date:  2018-03-20       Impact factor: 10.864

Review 9.  Quality of life in cirrhosis.

Authors:  Anthony Loria; Carey Escheik; N Lynn Gerber; Zobair M Younossi
Journal:  Curr Gastroenterol Rep       Date:  2013-01

10.  Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.

Authors:  Hiroyuki Nakanishi; Masayuki Kurosaki; Takanori Hosokawa; Yuka Takahashi; Jun Itakura; Shoko Suzuki; Yutaka Yasui; Nobuharu Tamaki; Natsuko Nakakuki; Hitomi Takada; Mayu Higuchi; Yasuyuki Komiyama; Tsubasa Yoshida; Kenta Takaura; Tsuguru Hayashi; Konomi Kuwabara; Sei Sasaki; Namiki Izumi
Journal:  J Gastroenterol       Date:  2015-11-26       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.